Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Qiagen N.V. QGEN
$45.08
-$0.46 (-1.02%)
На 18:00, 12 мая 2023
+21.03%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
10277537811.00000000
-
week52high
51.18
-
week52low
40.38
-
Revenue
2141518000
-
P/E TTM
25
-
Beta
0.38235200
-
EPS
1.85000000
-
Last Dividend
1.08907900
-
Next Earnings Date
04 мая 2023 г. в 13:00
Описание компании
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Equal-Weight | 14 дек 2021 г. |
| Redburn Partners | Buy | 14 окт 2021 г. | |
| Kepler Cheuvreux | Hold | Buy | 14 июл 2021 г. |
| Goldman Sachs | Neutral | 03 июн 2021 г. | |
| B of A Securities | Buy | Neutral | 06 окт 2020 г. |
| Citigroup | Buy | Buy | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| iShares TecDAX UCITS ETF (DE) | 1852570 | 20642 | 31 авг 2020 г. |
| Vanguard Total International Stock Index Fund | 3715620 | -34305 | 31 июл 2020 г. |
| MFS International Growth Fund | 2357430 | -79450 | 31 июл 2020 г. |
| MFS Institutional International Equity Fund | 1857470 | -19752 | 31 июл 2020 г. |
| Vanguard Capital Opportunity Fund | 6606700 | -115240 | 30 июн 2020 г. |
| PRIMECAP Odyssey Aggressive Growth Fund | 3318720 | -222780 | 30 июн 2020 г. |
| Victory Sycamore Established Value Fund | 2300000 | -433500 | 30 июн 2020 г. |
| PRIMECAP Odyssey Growth Fund | 1638650 | -673891 | 30 июн 2020 г. |
| BlackRock Event Driven Equity Fund | 6717130 | 3124230 | 31 мая 2020 г. |
| Statens Pensjonsfond Utland | 3613470 | 2083650 | 31 дек 2019 г. |
Новостная лента
Qiagen N.V. (QGEN) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 15:17
Qiagen N.V. (NYSE:QGEN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants John Gilardi – Vice President, Head of Corporate Communications and Investor Relations Thierry Bernard – Chief Executive Officer Roland Sackers – Chief Financial Officer Conference Call Participants Andrew Brackmann – William Blair Aisyah Noor – Morgan Stanley Dan Arias – Stifel Odysseas Manesiotis – Berenberg Dan Brennan – TD Cowen Casey Woodring – JPMorgan Patrick Donnelly – Citi John Sourbeer – UBS Operator Ladies and gentlemen, thank you for standing by.
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
28 апр 2023 г. в 13:39
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline
Zacks Investment Research
18 апр 2023 г. в 11:25
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers
Zacks Investment Research
06 апр 2023 г. в 13:42
In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
Zacks Investment Research
30 мар 2023 г. в 12:10
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.